“`html
10/13/2025 – 11:07 PM
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. This presentation marks a significant step in the company’s ongoing efforts to advance novel therapeutic approaches in oncology.
Presentation details are as follows:
Abstract title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window
Date and Time: Saturday, October 25, 2025; 11:45 AM – 12:15 PM ET
Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents
Location: Level 3, Ballroom AB, Hynes Convention Center, Boston, MA
The company is expected to release further details surrounding the scientific rationale and key data points related to AN4035 following the abstract’s publication on the AACR portal on October 22, 2025. Investors and industry analysts will be keenly watching for insights into the drug’s mechanism of action, preclinical efficacy, and potential for clinical translation. The promise of a broader therapeutic window, as highlighted in the abstract title, could represent a significant advantage in treating cancers driven by RAS mutations.
About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is positioning itself as a key player in the global oncology landscape. With R&D centers in both the U.S. and China, the company is strategically positioned to leverage scientific expertise and access diverse patient populations. Their therapeutic pipeline focuses on two key areas: next-generation PD-1/L1 modulation and RAS-targeted therapies. The presentation on AN4035 underscores the company’s commitment to exploring innovative approaches to address challenging targets such as RAS, which has historically been difficult to drug. The proprietary pan-RAS(ON) inhibitor payload used in AN4035 suggests a differentiated approach compared to existing RAS inhibitors, potentially offering improved efficacy and reduced toxicity.
Forward-Looking Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.
The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations
Email:
